Search

Author/Creator Colclough, N.

1. Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo). (December 2016)

Authors:
Ward, R.; Ashton, S.; Bianco, A.; Colclough, N.; Cross, D.; Cuomo, E.; Finlay, M.R.V.; Floch, N.; Fitzek, M.; Martin, M.; Menard, L.; McKerrecher, D.; O'Neill, D.; Orme, J.; Talbot, V.; Staniszewska, A.; Yates, J.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs. (December 2016)

Authors:
Colclough, N.; Ballard, P.G.; Barton, P.; Chen, K.; Cross, D.A.E.; Finlay, M.R.V.; Han, L.; Janefeldt, A.; Johnström, P.; Ward, R.A.; Wrigley, G.L.; Yan, Y.; Yates, J.W.T.; Zhang, D.; Zhang, Z.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search